Oral GLP-1 Tablets for Weight Loss
A new tablet-based option for medical weight management — starting with Wegovy® Tablets.
A once-daily tablet option for weight management
Wegovy® tablets offer an oral alternative for suitable adults who prefer a tablet instead of a weekly injection.
Prescription-only medicine. Suitability depends on BMI, medical history, current medicines and prescriber assessment.
What are oral GLP-1 tablets?
GLP-1 medicines are treatments that help support weight management by acting on appetite, fullness and food intake.
Until recently, GLP-1 weight-loss treatment has mainly been available as injections. Wegovy® tablets contain semaglutide and offer a once-daily oral option for suitable adults.
How do Wegovy® tablets work?
Wegovy® tablets contain semaglutide, a GLP-1 medicine that helps support weight management by acting on appetite, fullness and food intake.
Helps reduce appetite
GLP-1 treatment can help reduce hunger signals, making it easier for suitable patients to manage calorie intake.
Helps you feel fuller
Semaglutide can help increase feelings of fullness after eating, which may support smaller portions and better eating habits.
Supports long-term change
Wegovy® tablets are used alongside diet and physical activity to support weight loss and weight maintenance.
How do oral GLP-1 tablets compare with injections?
Oral GLP-1 tablets and injectable GLP-1 treatments can both support weight management, but they are taken in different ways. The right option depends on suitability, medical history, routine and prescriber assessment.
Oral GLP-1 tablets
- Taken as a tablet once daily.
- No injection device or needle needed.
- May suit patients who prefer tablets.
- Needs to be taken carefully around food, drink and other oral medicines.
GLP-1 injections
- Usually taken as an injection once weekly.
- May suit patients who prefer less frequent dosing.
- Does not usually require the same daily fasting routine.
- Requires comfort with using an injection pen.
What do the weight loss results show?
Novo Nordisk clinical trial data shows strong weight-loss results for both Wegovy® tablets and weekly Wegovy® injections. These figures come from different studies, so they should not be treated as a direct tablet-versus-injection comparison.
Wegovy® tablets 25 mg daily
Average body weight loss over 64 weeks when oral semaglutide 25 mg was taken as intended in Novo Nordisk clinical trial data.
The wider trial analysis showed 13.6% average weight loss, compared with 2.2% with placebo.Wegovy® injection 2.4 mg weekly
Average body weight loss shown in major weekly semaglutide injection trials over around 68 weeks.
Weekly injections remain a strong evidence-based option for suitable adults who prefer weekly dosing.The 16.6% figure reflects participants taking treatment as intended in Novo Nordisk OASIS 4 trial data for oral semaglutide 25 mg over 64 weeks. The wider trial analysis showed 13.6% average weight loss. Trial results are averages, individual results vary, and the tablet and injection studies were not the same trial.
Different routines. Strong evidence for both.
Oral GLP-1 tablets
GLP-1 injections
Your Wegovy® tablet journey
Wegovy® tablets are usually started at a low daily dose and increased step by step. This gradual approach helps your body adjust while your prescriber reviews suitability and tolerance.
Starting dose
Treatment begins with a low daily dose to help your body get used to oral semaglutide.
First increase
If suitable, the dose is increased as part of the planned step-up schedule.
Building dose
Your prescriber will consider tolerance, side effects and clinical suitability before continuing.
Maintenance dose
The 25mg daily dose is the ongoing dose used for weight management where clinically appropriate.
Do not increase your dose unless instructed to do so. Treatment suitability, dose progression and ongoing prescribing depend on your consultation, tolerance, side effects and prescriber assessment.
Could oral GLP-1 treatment be suitable for you?
BMI is one of the factors used to assess suitability for weight management treatment. Your final suitability depends on a full clinical review.
BMI calculator
Enter your height and weight to estimate your BMI.
General suitability guidance
Weight management treatment may be considered for adults who meet BMI criteria and are clinically suitable after assessment.
This calculator is for information only. It does not confirm eligibility or replace clinical assessment.
What could weight loss look like for you?
Enter your current weight to see what different percentage weight-loss milestones could mean in kilograms.
Early milestone
Estimated weight:
Meaningful progress
Estimated weight:
Strong result
Estimated weight:
Trial-level average
Estimated weight:
The 16.6% figure reflects Novo Nordisk OASIS 4 trial data for oral semaglutide 25mg where treatment was taken as intended. The wider trial analysis showed 13.6% average weight loss. Individual results vary.
Sources used for this page
This page has been written using regulatory information, manufacturer clinical trial data and published clinical evidence relating to Wegovy® tablets and semaglutide treatment.
-
MHRA: First GLP-1 tablet for weight loss approved in the UK
UK approval information for Wegovy® semaglutide tablets, including prescription-only status, BMI suitability criteria and use alongside reduced-calorie diet and increased physical activity.
View MHRA source -
Novo Nordisk: Wegovy® pill approval and OASIS trial programme
Manufacturer information on the Wegovy® pill, including oral semaglutide 25 mg once-daily clinical trial data and the 16.6% mean weight-loss figure when treatment was adhered to.
View Novo Nordisk source -
New England Journal of Medicine: Oral Semaglutide 25 mg in Adults with Overweight or Obesity
Published OASIS 4 clinical trial paper evaluating oral semaglutide 25 mg once daily in adults with overweight or obesity.
View NEJM study -
ClinicalTrials.gov: OASIS 4 trial record
Trial registration for the oral semaglutide OASIS 4 study, including study design and dose-escalation information.
View ClinicalTrials.gov record - Official patient information leaflet Patient leaflet information for Wegovy® tablets, including dosing, administration, pregnancy advice, side effects and safety warnings.
